Stock Taper
SCREENER COMPARE ANY 2 STOCKS
KYMR
KYMERA THERAPEUTICS, INC.
NASDAQ
$118.15
▼ DOWN 1.73% (-2.08)

KEY STATISTICS

Market Cap$9.72 B
52w High$130.05
52w Low$39.84
Dividend Yield—
Frequency—
P/E-36.92
Volume415.93K
Shares Out.82.26M

COMPANY

LEADERSHIP

Nello Mainolfi
CHIEF EXECUTIVE
Nello Mainolfi

COMPENSATION 2026

Salary$693,000
Stock Awards$0
Incentive Plan Pay$519,750
All Other Comp.$14,000
Total$8,545,609

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 21, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
273

PRICE TARGET

Target High$155.00
Target Low$97.00
Target Median$135.00
Target Consensus$129.64

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$3.82M
NOV
3
TUE

PRICE

$118.15 ▼ DOWN 1.73% (−$2.08)
$118$119$1209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM118.15

About Kymera Therapeutics, Inc.

https://www.kymeratx.com ↗

Kymera Therapeutics is a biopharmaceutical company developing small molecule degraders targeting disease-causing proteins, with programs in immunology, oncology, and autoimmune diseases, headquartered in Watertown, MA.

INDUSTRY

Biotechnology

A PRODUCT KYMERA THERAPEUTICS, INC. IS KNOWN FOR

KT-621
KT-621

KT-621 is an oral STAT6 degrader by Kymera, developed to treat immuno-inflammatory diseases like atopic dermatitis and asthma with biologic-like efficacy.

COMPETITORS

COMPETITOR
ARVN COMPARE
CCCC COMPARE
FHTX COMPARE
GLUE COMPARE
NRIX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
175
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.01% · 2.1M
IWM
0.25% · 1.6M
XBI
1.37% · 1.4M
SCHA
0.16% · 301.5K
TCAF
0.41% · 288.0K
DFAS
0.12% · 152.3K
XRS2.F
0.24% · 57.2K
FTXH
0.57% · 50.4K
FESM
0.09% · 50.2K
LABU
0.93% · 49.2K
HAPS
2.06% · 30.4K
RSSL
0.23% · 29.9K
JHMM
0.05% · 23.5K
PRFZ
0.09% · 22.4K
BBSC
0.25% · 15.4K
BKMC
0.17% · 9.2K
GSSC
0.06% · 5.6K
AVUS
0.00% · 5.0K
BBC
0.83% · 3.6K
TILT
0.02% · 3.1K
BIB
0.34% · 2.9K
STXK
0.35% · 2.5K
RFLR
0.23% · 1.8K
ESSC
0.42% · 1.5K
HLTH
2.29% · 1.5K
TMFX
0.39% · 1.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
93.41%
HOLDERS
352
TOP 12 OF 352 · RANKED BY POSITION SIZE
Fmr LLC
12.3M sh · $1.42B
Baker Bros. Advisors LP
8.7M sh · $992.73M
Avoro Capital Advisors LLC
7.5M sh · $857.13M
Price T Rowe Associates Inc /Md/
7.1M sh · $815.65M
Vanguard Group Inc
6.3M sh · $487.69M
T. Rowe Price Investment Management, Inc.
6.3M sh · $717.52M
Blackrock, Inc.
5.5M sh · $635.07M
Bvf Inc/Il
5.5M sh · $458.32M
Wellington Management Group Llp
5.2M sh · $294.08M
Atlas Venture Life Science Advisors, LLC
4.9M sh · $277.14M
Blackrock Inc.
4.2M sh · $124.04M
Siren, L.L.C.
3.4M sh · $194.03M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Rooney Terence
Purchase · 76.0K shares
2026-07-27
★
OFFICER: CHIEF MEDICAL OFFICER
Rooney Terence
Purchase · 38.0K shares
2026-07-27
★
Rooney Terence
— · —
2026-07-27
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Mainolfi Nello
Purchase · 50.0K shares
2026-07-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 10
OVERWEIGHT 6
OUTPERFORM 3
SECTOR PERFORM 1
PEER PERFORM 1
21 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT Guggenheim BUY Mizuho OUTPERFORM RBC Capital SECTOR PERFORM B of A Securities BUY Truist Securities BUY B. Riley Securities BUY Canaccord Genuity BUY

SECTORS PEERS

PEERPRICE
PRAX$344.75COMPARE
CRNX$84.84COMPARE
IMVT$41.20COMPARE
ACAD$29.11COMPARE
VKTX$32.16COMPARE
NAMS$25.90COMPARE
AAPG$18.28COMPARE